What advantages and disadvantages does Shockwave lithotripsy offer you for treatment of calcified arteries?

Shockwave IVL
140 videos
Intravascular Lithotripsy (IVL) offers significant benefits as an additional calcium modification tool in your armamentarium, allowing you to:
MINIMIZE TRAUMA - Minimize trauma to soft tissue...
Intravascular Lithotripsy (IVL) offers significant benefits as an additional calcium modification tool in your armamentarium, allowing you to:
MINIMIZE TRAUMA - Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
OPTIMIZE OUTCOMES - Optimize stent delivery, expansion and apposition while reducing complications and cost escalation
SIMPLIFY PROCEDURES - Simple and intuitive system that makes complex calcified coronary procedures more predictable
Find out more about Shockwave Lithotripsy: www.rutherfordmedicine.com/shockwavemedical
About Shockwave IVL
Simplify your procedures with Intravascular Lithotripsy (IVL) by safely modifying intimal and medial calcium to achieve optimal outcomes while minimising trauma, complications and costs due to its unique MOA.
Prior to use, please reference the instructions for use and important safety information: ShockwaveC2ISI.com
ShockwaveIVL.com
Speakers
Prof Javier Escaned is Head of Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). He...
Prof Javier Escaned is Head of Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). He trained as a cardiologist the United Kingdom before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. A skilled interventionalist with over 30 years of experience, he regularly serves as live case operator and educationalist in global events like EuroPCR, TCT or the ESC Congress. He is author of over 500 PubMed indexed scientific articles (h-index 71) on topics that include complex PCI in multivessel disease (principal investigator of SYNTAX II study), left main and chronic total occlusions, and secondary revascularization. His track record in coronary physiology includes being investigator on pivotal FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR (since 2010), and developer of new methods for the assessment of microvascular and non-obstructive coronary disease. Recent / ongoing trials as Co-PI include ADVISE, ADVISE II, DEFINE FLAIR and ABSORB II PHYSIOLOGY, being investigator also in ILUMIEN I and IV, COMBINE and other studies on coronary imaging. He is currently Deputy Editor for Interventional Cardiology of the European Heart Journal, as well as editor of two large textbooks: “Coronary Stenosis.Imaging, Structure and Physiology”, (co-editor Patrick Serruys) and “Physiological Assessment of Coronary Stenoses and the Microcirculation) (co-editor Justin Davies). Current or recent board positions in scientific societies include EuroPCR, EAPCI, EuroCTO and the ESC Working Group of Coronary Pathophysiology and Microcirculation. Some of his additional interests are philosophy, education and music.
Start a conversation